Several possible studies
Story checked
If only Diana Spiegelberg had AI-based tools… – For Better Science (opens in a new tab)
forbetterscience.com · 2026-09-28
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
If only Diana Spiegelberg had AI-based tools… – For Better Science
forbetterscience.com · 2026-09-28
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The 8 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- The study this story reportsmentioned without context
Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy
Frontiers in Oncology · 2025
- The study this story reportsmentioned without context
Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer
Scientific Reports · 2023
- The study this story reportsmentioned without context
Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
Frontiers in Oncology · 2020
- The study this story reportsmentioned without context
The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model
Frontiers in Oncology · 2020
- The study this story reportsmentioned without context
The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors
Cancer Research · 2018
- The study this story reportsmentioned without context
The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells
Oncotarget · 2015
- The study this story reportsmentioned without context
10.3389/fonc.2026.1823700/full
- The study this story reportsmentioned without context
10.3389/fonc.2026.1824012/full
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 8Not checkedThe Swedish National Board for Assessment of Research Misconduct (NPOF) found Diana Spiegelberg guilty of research misconduct, while her coauthors were generally judged only negligent.View evidenceHide evidence
As statedacross several papers
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 8Not checkedThe investigation concerned five cancer research papers from the Uppsala group, most involving onalespib and radiotherapy or other cancer-drug combinations, and the board concluded that several figures had been falsified or altered without justification.View evidenceHide evidence
As statedfive publication[s]
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 8Not checkedFor the 2025 Frontiers in Oncology glioblastoma paper, the article says NPOF found Figure 2D falsified because incorrect images were shown, despite Spiegelberg’s explanation that the images were only representative and that the issue was missed by reviewers and image-screening tools.View evidenceHide evidence
As statedone figure
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 8Not checkedFor the 2023 Scientific Reports thyroid-cancer paper, the article says NPOF found Figure 3D falsified and judged Spiegelberg responsible for moving, flipping, rotating, and annotating images during figure layout.View evidenceHide evidence
As statedone figure
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 8Not checkedFor the 2020 Frontiers in Oncology cisplatin/onalespib paper, the article says NPOF found Figure 3A falsified because an incorrect image was shown and the correct one omitted.View evidenceHide evidence
As statedone figure
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 8Not checkedFor the 2020 colorectal-cancer model paper, the article says NPOF found Figures 3C and 2E falsified and says Spiegelberg created the forged figures.View evidenceHide evidence
As statedtwo figures
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 8Not checkedFor the 2018 Cancer Research paper, the article says NPOF found Figure 2C falsified and also treated a spliced western blot in Figure 1A as misconduct, with Spiegelberg again found guilty of gross negligence.View evidenceHide evidence
As statedtwo figure issues
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 8 of 8Not checkedThe article says Spiegelberg and some coauthors argued the image problems were oversights or copy-paste/layout mistakes, that the conclusions were not invalidated, and that AI-assisted validation tools were not widely available at the time.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
Crossref, PubMed, Europe PMC · 20 candidate papers
Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy
Frontiers in Oncology · 2025 · Crossref
Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer
Scientific Reports · 2023 · Crossref
Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
Frontiers in Oncology · 2020 · Crossref
The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model
Frontiers in Oncology · 2020 · Crossref
The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors
Cancer Research · 2018 · Crossref
And 15 more candidates considered.